Management

This page includes content on healthcare management, including health system, hospital, department and clinic business management and administration. Areas of focus are on cardiology and radiology department business administration. Subcategories covered in this section include healthcare economics, reimbursement, leadership, mergers and acquisitions, policy and regulations, practice management, quality, staffing, and supply chain.

https://www.dynocardia.care/

NIH awards commercialization grant for wrist-worn continuous ICU-grade blood pressure monitor

Dynocardia has now received nearly $5.1 million in funding from the NHLBI to help speed commercializing its wrist-worn monitor to avoid the need for invasive catheter BP monitoring.

Example of an automated artificial intelligence (AI) assessment of soft coronary plaque from a CT scan from the vendor Cleerly. The AI gives a very detailed report of all the plaque in all the coronary vessels. Some cardiology experts believe this may be the way of the future in screening patients for early coronary disease and monitoring the impact of prevention efforts such as statins to determine if more aggressive treatments are needed.

Medicare administrative contractors approve coverage of AI-enabled quantitative CT

Four of the seven Medicare Administrative Contractors (MACs) announced they will now cover artificial intelligence-enabled quantitative coronary tomography (AI-QCT) and coronary plaque analysis (AI-CPA). 

HeartFlow Plaque Analysis

CMS updates Medicare coverage for AI-powered coronary plaque assessments

The new policy goes into effect in November, improving Medicare coverage for a technology that has rapidly gained momentum in recent years.

Cardiologists have performed what they believe to be the world’s first substernal lead extraction, sharing their experience in JACC: Case Reports.[1]The device being extracted, Medtronic’s Aurora EV-ICD, received U.S. Food and Drug Administration (FDA) approval in October 2023.

Cardiologists perform world’s first substernal lead extraction

The 49-year-old patient was not in pain or suffering any complications, but he wished to have his extravascular ICD removed once his symptoms improved. The care team agreed to extract it after a long discussion, and they said it was "easier than expected." 

pharmaceutical drug approval process

FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

IV hospital room intravenous drip solution

ACR shares guidance for radiology providers facing IV supply shortages after hurricane

Baxter’s North Cove manufacturing site was significantly impacted by unprecedented rain and storm surge from Hurricane Helene hitting western North Carolina. 

Video of Jamshid Maddahi, MD, UCLA, explaining why flurpiridaz will change cardiac imaging and increase the adoption of PET cardiac imaging.

A closer look at how FDA's flurpiridaz approval will impact nuclear cardiology

The newly approved PET radiotracer is expected to improve patient care significantly. “We have been able to reach the pinnacle of myocardial perfusion imaging with flurpiridaz," one expert said.

V-Wave has gained considerable attention or its Ventura Interatrial Shunt System, a small implantable device designed to reduce pressure on the left atrium and the lungs in patients with heart failure with reduced ejection fraction (HFrEF). The Ventura device includes a nitinol hourglass-shaped frame that anchors to the patient’s fossa ovalis in a way that prevents migration or embolization. It is implanted via an interventional procedure with fluoroscopy and echocardiography guidance.

Johnson & Johnson completes V-Wave acquisition

While the initial purchase price was $600 million, the final amount could reach approximately $1.7 billion if certain milestones are met. V-Wave's Ventura Interatrial Shunt System for HFrEF has gained considerable interest in recent years, and Johnson & Johnson was an early investor in the technology back in 2016.

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Trimed Popup
Trimed Popup